Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

y participants were encouraging. Genzyme expects to release

results by mid year for a larger number of patients, including results

for those patients who have completed the one year trial. Final

results for all trial participants will be available in the first

quarter of 2009. Genzyme is currently developing clinical trial

protocols for two Phase 3 studies of Genz-112638, and the company

anticipates initiating these studies early next year. Genzyme believes

that this oral product may offer a more convenient treatment option for

some patients.

Mipomersen for high-risk cardiovascular disease

Genzyme expects to finalize its license of mipomersen from Isis

Pharmaceuticals in the second quarter and subsequently communicate a

development plan for the product. Mipomersen is a lipid-lowering agent

being developed primarily for patients at significant cardiovascular

risk who are unable to achieve target cholesterol levels with statins

alone or who are intolerant of statins. The product offers an

innovative approach to addressing a serious unmet medical need, and

Genzyme believes it could prove to be the most effective lipid-lowering

agent for high risk cardiovascular disease patients for whom

conventional therapies are not sufficient. The product may provide

significant benefit over the standard of care and targets a well-defined

and severely ill patient population. Mipomersen is currently being

studied in a Phase 3 clinical trial involving patients with homozygous

familial hypercholesterolemia.

This press release contains forward-looking statements regarding Genzyme's financial outlook and business plans and strategies, including without limitation: its Q2 2008, YE 2008 and YE 20011 earnings guidance; its anticipated CAGR through 2011; its expectations for approval of Myo
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... INDIANAPOLIS , Oct. 30, 2014 A ... Battelle Technology Partnership Practice, takes an in-depth look at ... innovation outputs that have resulted over two different time ... also provides a view of future opportunities for investment ... Indiana report shows gains in innovation ...
(Date:10/27/2014)... Carolina (PRWEB) October 27, 2014 Ryan ... earlier this month to sit down with Bryan Hamilton, the ... RPG Solutions to discuss talent in the Research Triangle region ... topics that were highlighted at the roundtable include the ... Triangle, the significance of work/life balance and the unique role ...
(Date:10/27/2014)... , Oct. 27, 2014 Kalorama Information ... recent Ebola concern in the United States ... virus.  The healthcare market researcher said the FDA,s Emergency Use ... vitro diagnostic tests for the detection of the Ebola ... proved useful.  Kalorama routinely assess the IVD industry and ...
(Date:10/27/2014)... The report “Smart Highway Market ... Communication, Monitoring), and by Display (Variable Message Signs, ... the global market into various sub-segments with in-depth ... the drivers and restraints for this market with ... 75 market tables and 37 figures spread through ...
Breaking Biology Technology:New report shows Indiana's gains in life sciences innovation capital outpace the nation 2New report shows Indiana's gains in life sciences innovation capital outpace the nation 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 4New report shows Indiana's gains in life sciences innovation capital outpace the nation 5Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4
... expressing green fluorescent protein (GFP) in their retina cells ... video cameras, creating a real time computer record of ... the open access journal BMC Biotechnology , will ... and aging. , John Tower led a team of ...
... for Equipment and Service Excellence at the 54th Annual ... , IRVINE, Calif., Dec. 16 Masimo ... CO-Oximetry and Measure-Through-Motion and Low-Perfusion pulse oximetry, announced that ... notification system, Masimo Patient SafetyNet, was featured in a ...
... , - BiomarkerCenter of Excellence Established in ... 16 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: ... that it has purchased a minority equity stake in Caprion Proteomics, ... further enhance its biomarker service offerings to clients. , ...
Cached Biology Technology:AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 2AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 3AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 4AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 5Covance Purchases Equity Stake in Caprion Proteomics 2Covance Purchases Equity Stake in Caprion Proteomics 3Covance Purchases Equity Stake in Caprion Proteomics 4Covance Purchases Equity Stake in Caprion Proteomics 5
(Date:10/29/2014)... in the living world compete with members of ... how much they invest into their competitive ability. ... get access to high-quality resources, while others seem ... the lower-quality resources that are left over for ... and human societies seems to fluctuate considerably over ...
(Date:10/29/2014)... study on a large cohort of kidney cancer patients ... the disease -- and reveals an apparent link between ... particularly in Romania. , The research, by an international ... Genome Quebec Innovation Centre in Montreal, underscores the importance ... The compound, found in plants of the Aristolochia genus, ...
(Date:10/28/2014)... North America, Europe and China have published a paper ... Sciences that reveals important details about key transitions ... From strange and exotic algae, mosses, ferns, trees and ... and vegetables we eat and the ornamental plants adorning ... a billion years of history., "Our study generated DNA ...
Breaking Biology News(10 mins):Evolution of competitiveness 2Evolution of competitiveness 3Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3New study uses DNA sequences to look back in time at key events in plant evolution 2New study uses DNA sequences to look back in time at key events in plant evolution 3
... ability to pay attention to relevant information while ignoring ... to focus and filter out "noise," we could not ... attention in the brain, the cellular mechanisms responsible for ... now., In a study appearing in the journal ...
... Some of the top scientists in the nation, ... members, will make presentations at a University of Louisville-hosted ... Symposium: Anatomical and Functional Modularity of the Cerebral Cortex," ... Conference Center, 200 Abraham Flexner Way. Admission is free, ...
... Kuala Lumpur, Malaysia, St. Louis, MO and Cold Spring Harbor, NY-- ... Shell, that regulates yield of the oil palm tree. The fruit ... one-half of the supply of edible vegetable oil worldwide, and provide ... discovery, the product of a multiyear effort to provide a high-quality ...
Cached Biology News:Neuroscience symposium bringing top scientists to Louisville, Aug. 1-2 2Full genome map of oil palm indicates a way to raise yields and protect rainforest 2Full genome map of oil palm indicates a way to raise yields and protect rainforest 3
...
Request Info...
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
Biology Products: